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The actions of androgens are mediated through an androgen receptor (AR), and AR activity is 
modulated by coregulators. The aim of this study was to assess the action of androgens in the 
expression of AR and the coregulators FHL-2 and SHP-1 in human non-transformed epithelial prostatic 
cells (HNTEP) treated with androgens. Prostate tissues were obtained from 12 patients between 60 and 
77 years of age. HNTEP cells were grown in basal medium and treated with DHT in different conditions. 
HNTEP cells under treatment with DHT (10
-13 
M) induced an increase in FHL-2 expression. In turn, high 
DHT concentrations (10
-8
 M) induced an increase in the expression SHP-1. The present data suggest that 
the SHP-1 and FHL-2 genes play a role in the control of responsiveness and androgen-dose-dependent 
cell proliferation in HNTEP cells. Further studies are needed to assess the influence of androgens in AR 
and its coregulators and the implications in the pathophysiology of prostate diseases. 
 





Androgens are mediators of a wide range of 
developmental and physiological responses. The effects 
of androgens occur through the androgen receptor (AR). 
The androgen interactions with the AR result in 
transcriptional activation of target genes which are 
important in male sexual differentiation and puberal 
sexual maturation (Marker et al., 2003). AR is a ligand 
inducible transcriptional factor, member of the nuclear
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receptor superfamily that mediates the expression of 
target genes in response to specific stimulus (Aranda and 
Pascual, 2001). The human AR gene is localized in the 
chromosome X at the q11-q12 position. There are eight 
exons and the gene shares a characteristic structure with 
other nuclear receptors, four domains: the ligand binding 
domain (LBD) containing activation function domain 2 
(AF-2), the zinc-finger-type DNA-binding domain (DBD), 
a hinge region and the variable NH2- terminal tran-
sactivation domain (NTD) possessing activation function 
domain 1 (AF-1).  
AF-1 acts as a ligand-independent manner and can be 
more active when in contact with basal transcription 
factors, while the activity of AF-2 requires the ligand 
binding. Also, the interaction between NTD and LDB 
could also be necessary for the activation of AR (Dehm 
and Tindall, 2007; He et al., 2000). 
Androgens play an important role in controlling the 
growth of the normal prostate gland, and also in 
promoting benign prostate hyperplasia (BPH) and 
prostate carcinoma (PCa). Histologic evidence of BPH is 
found in 50% of men at the age of 50 and up to 90% of 
males at the age of 80 (Roehrborn et al., 2006). The 
pathogenesis of BPH is still poorly understood, but there 
are two accepted permissive factors: the presence of 
circulating androgens and advancing age (Untergasser et 
al., 2005). The proliferative effects of androgens in 
prostate are controversial; some studies demonstrated a 
biphasic effect of androgen action in prostatic cells 
proliferation where lower androgen concentrations have a 
maximum mitogen effect whereas higher concentrations 
do not (Joly-Pharaboz et al., 2000; Joly-Pharaboz et al., 
1995; Lee et al., 1995; Shao et al., 2007; Sonnenschein 
et al., 1989).  
In contrast, other studies were not able to show any 
effect of androgens, at different concentrations, on cell 
proliferation of normal, hyperplasic or tumoral prostatic 
cells (Berthon et al., 1997; Heisler et al., 1997; Krill et al., 
1999). Androgen concentrations are determinant to 
prostate enlargement and dependent on AR activity (Li et 
al., 2007; Yuan et al., 2006). Prior to androgen binding, 
AR is held inactive through association with heat shock 
proteins. Androgen binding releases inhibitory proteins 
and the AR translocates to the nucleus, where it interacts 
with DNA sequences, called androgen responsive 
elements (ARE). After binding to ARE, AR is able to 
recruit all the compounds of the transcriptional machinery 
for target genes (Balk and Knudsen, 2008).  
Activation of gene expression is one aspect of AR 
signaling. Repressed or activated androgen-responsive 
genes appear to play important roles in regulating cell 
growth and differentiation. The activation of AR by 
androgens is a complex process involving a large number 
of activating and repressing proteins called coregulators. 
Several studies have indicated that altered expression of 
these molecules may modify transcriptional activity of AR 





to the progression of prostatic pathologies (Heemers and 
Tindall, 2007; Urbanucci et al., 2008, Muramatsu et al., 
2013, Toropainen et al., 2015). 
SHP-1 (short heterodimer partner) is an orphan nuclear 
receptor which interacts with a large variety of nuclear 
receptors and has been shown to be expressed in 
androgen target tissues (Johansson et al., 1999). Gobinet 
et al. (2001) demonstrated that SHP-1 interacts both in 
vitro and in vivo with the full-length AR and inhibited both 
the AR ligand-binding domain and the N-terminal domain 
dependent transactivation. SHP-1 could also inhibit AR 
activity by competing with AR coactivators. 
FHL-2 is an LIM-only member of the LIM protein 
superfamily. It is a selective agonist-dependent 
coactivator of the AR, but not of other nuclear receptors. 
FHL-2 increases the transcriptional activity of the AR in 
an agonist and AF-2 dependent manner. Also a study 
showed a FHL2 overexpression in prostatic cells and in 
the presence of DHT, endogenous FHL2 bind at the ARE 
to enhance AR-transcriptional activity (Kollara and 
Brown, 2010). It is expressed in myocardium and in the 
prostate gland (Muller et al., 2000). The action of 
androgens in AR is controversial and complex, because it 
has become clear that the transcriptional activity of AR is 
regulated by coregulators, including both coactivators 
and corepressors, by various mechanisms. The aim of 
the present study was to determine the effect of 
androgens at different concentrations on AR expression 
and the coregulators SHP-1 and FHL-2 in HNTEP cells. 
 
 
MATERIALS AND METHODS 
 
Cell culture  
 
Samples of prostatic tissue were obtained from retropubic 
prostatectomy from 12 patients between 56 and 75 years of age, 
diagnosed with BPH. Patients with malignant tumors were 
excluded. The study protocol was approved by the local Ethics 
Committee (UFRGS, protocol 99001). Informed consent was 
obtained from all subjects. HNTEP cells were cultured as previously 
described (Brum et al., 2003). Briefly, after removal of blood clots, 
prostatic tissue was washed with Hank’s balanced salt solution 
(HBSS, Gibco BRL Grand Island, N.Y., USA) plus kanamycin (0.5 
mg/ml) (Sigma Chem Co., St Louis, MO,USA), and then finely 
minced into 2 to 3 mm pieces. Tissue fragments were treated with 
type IA collagenase (7.5 mg/g of tissue) (Sigma Chem Co., St 
Louis, MO, USA) in HBSS. Enzymatic digestion proceeded for 3 h 
at 37°C with gentle shaking. The enzymatic reaction was 
interrupted with the addition of warm 199 culture medium (Gibco 
BRL Grand Island, N.Y., USA) with kanamycin (0.5 mg/ml) and 10% 
fetal bovine serum (FBS) (Gibco BRL Grand Island, N.Y., USA). 
Epithelial cells were separated by differential filtration. Cell 
suspensions were distributed into 35 mm tissue culture dishes 
(Corning, Glassworks, NY, USA), 1 × 10
5
 cells per dish, or into 24 
well tissue culture plates (NUNC
TM
, Denmark), 2 × 10
4
 cells/ml per 
plate, and maintained at 37°C in a humidified atmosphere of 95% 
air/5% CO2 (NuAire, Inc., Minnesota, USA). In addition, since it is 
hard to observe the stimulatory effect of androgen on cell growth in 
vitro, we used a culture medium that was free of growth factors 
other than those present in FBS. Basal medium consisted of 199 






charcoal-stripped FBS (cFBS). Cultures were kept in the same 
medium for the first 2 days and then the medium was changed 
every two days.  
 
 
Western blot  
 
Protein was obtained from the extraction of RNA with Trizol® 
(Invitrogen, Carlsbad, CA, USA) reagent following the protocol of 
the manufacturer. The protein concentration was determined by the 
Bradford method. Sodium dodecyl sulfate (SDS) polyacrylamide gel 
eletrophoresis (8%) was carried out using a miniprotein system 
(Bio-Rad, Hercules, CA, USA) with broad-range molecular weight 
standards (Bio-Rad, Hercules, CA, USA). Protein (30 µg) was 
loaded in each lane with loading buffer containing [(0.375 M Tris 6.8 
pH), 50% glycerol, 10% SDS, 0.5 M dithiothreitol, and 0.002% 
bromophenol blue]. Samples were heated at 100°C for 2 min prior 
to gel loading. After eletrophoresis, proteins were transferred to 
nitrocellulose membranes using an eletrophoretic transfer system at 
110 V for 1 to 2 h. The membranes were then washed with TTBS 
(20 mM Tris-HCl, 7.5 pH; 150 mM NaCl; 0.05% Tween-20, 7.4 pH) 
and 8% nonfat dry milk for 90 min. The membranes were incubated 
overnight at 4°C with the primary antibody diluted in TTBS. A rabbit 
polyclonal antibody for AR (2 µg/ml) (Upstate Biotechnology) was 
used. After washing, the membranes were incubated for 2 h at 
room temperature with secondary antibody (1:20.000) (anti-rabbit 
IgG peroxidase conjugated; Upstate Biotechnology), washed with 
TBS (20 mM Tris-HCl; 150 mM NaCl, 7.5 pH), and developed with 
the chemiluminescence Western Blot system (Amersham 
Biosciences) followed by apposition of the membranes to 
autoradiographic films (Kodak X-Omat) exposure for 15 to 60 s. 
Ponceau S staining was used as protein loading control. 
 
 
Extraction of RNA and synthesis of cDNA 
 
Cells were grown in serum deprived basal medium for 4 h, and then 
treated with DHT or ethanol vehicle in different conditions. Cultured 
Prostatic cells were washed twice with PBS and homogenized in 
phenol-guanidine isothiocyanate (Trizol, Invitrogen, Carlsbad, CA, 
USA). Total RNA was extracted with chloroform and precipitated 
with isopropanol by 12.000 xg centrifugation at 4°C. The RNA pellet 
was washed twice with 75% ethanol, resuspended in 
diethylpyrocarbonate-treated water, and quantified by light 
absorbance at 260 nm. First strand cDNA was synthesized from 1 
g total RNA, using the SuperScript Preamplification System 
(Invitrogen, Carlsbad, CA, USA). After denaturing the template RNA 
and primers at 65°C for 5 min, 50 U of reverse transcriptase was 
added in the presence of 20 mM Tris-HCl (8.4 pH) plus 50 mM KCl, 
2.5 mM MgCl2, 0.5 mM dNTP mix and 10 mM dithiothreitol, and 
incubated at 42°C for 50 min. The mixture was heated at 70°C for 
interruption of the reaction and incubated with 2 U Escherichia coli 
RNase for 20 min at 37°C for destruction of untranscribed RNA. 
 
 
Real-time PCR conditions 
 
Amplification and detection were performed with the MiniOpticon 
Real Time PCR detection system (Bio- Rad Life Scicence 
Research, USA). Duplicate samples were used. The PCR mixture 
contained 1.25 μl of SYBR green, 2 ng of cDNA at 1:50 dilution, 3 
mM of MgCl2, 20 mM Tris-HCl (8.4 pH) plus 50 mM KCl ,0.2 mM 
dNTP mix, 1.25 U of taq polymerase and 0.4 M of each primer in a 
25 μl of final volume. The reaction conditions were 94°C for 2 min 
for initial denaturation and the cycling conditions were designed for 
each gene. The fluorescence emitted by SYBR green I was 
measured in every cycle at the end of elongation step. The reaction 
conditions were  94°C for 2 min for hot-start, and 35 cycles of  94°C 




for 30 s, 55°C for 40 s and 72°C for 40 s for the AR gene, 39 cycles 
of 94°C for 40 s, 58°C for 40 s and 72°C for 40 s for the SHP-1 
gene and 39 cycles of 94°C for 40 s, 59°C for 40 s and 72°C for 40 
s for the FHL-2 gene. The sequences of primers employed were: 
AR gene sense 5’ CATGGTGAGCAGAAGTGCCCTATC3’ 
antisense 5’ TCCCAGAGTCATCCCTGCTTCAT 3’ (Taplin et al., 
1995), SHP-1 gene sense 5’ CAGCTATGTGCACCTCATCG 3’ 
antisense 5’AGCCACCTCAAAGGTCACAG3’ 
(http://frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi) and FHL-2 
gene sense 5’ AAACTCACTGGTGGACAAGC 3’   antisense 
5’AGATGAAGCAGGTCTCATGC 3’  (http://frodo.wi.mit.edu/cgi-
bin/primer3/primer3_www.cgi). For normalization of the expression 
levels, the expression of β2-microglobulin (sense: 5’ 
ATCCAGCGTACTCCAAAGATTCAG3’, antisense: 5’ 
AAATTGAAAGTTAACTTATGCACGC 3’ (Taplin et al., 1995), was 
used as a housekeeping gene.   
 
 
Standard curves and efficiency 
 
All samples were automatically processed for melting curve 
analysis of amplified cDNA. The Tm (melting temperature) is specific 
to each amplicon. Standard curves were created by plotting the CT 
(cycle threshold) values of the real-time PCR performed on dilution 
series of standard. The real-time PCR assay was analyzed in the 
linear phase, and a linear function was fitted of the log of relative 
fluorescence versus cycle number with a typical R
2 
value greater 




=0.881 and FHL-2 R
2






Data are reported as means and standard error of mean (SEM). 
Analysis of the data revealed a normal distribution. Differences 
between groups were assessed by analysis of variance, followed by 
Duncan’s test. All analysis was performed using the Statistical 
Package for Social Sciences (SPSS, Chicago, IL, USA). Data were 





The action of DHT treatment on AR, SHP-1 and FHL-2 
mRNA levels in HNTEP cells was estimated by 
quantitative analysis. To confirm the presence of the AR 
in HNTEP cells, we evaluated the protein levels of AR 
after 1 and 2 h of incubation (Figure 2). The AR mRNA 





M) alone or in association with 
hydroxyflutamide (OH-FLU) at 10
-6 
M and no effect on AR 
gene expression was observed (Figure 3) in these 
conditions. The SHP-1 gene expression was evaluated 
after different concentrations of DHT after 4h of 
incubation and we observed an increase in SHP-1 mRNA 
levels with the higher dose of DHT (10
-8 
m) in comparison 
with the control group (data not show). FHL-2 levels in 
HNTEP cells were analyzed after 4h of treatment with 




m) alone or in 
association with the anti-androgen agent 
hydroxyflutamide (Oh-Flu) at 10
-6 
m. The coactivator of 
AR, FHL-2, showed an increase in mRNA levels in the 
group treated with the lower dose of androgen (10
-13 
m 
DHT) in comparison with the other (Figure 4). 
 










Figure 1. Standard curves of real-time PCR. Standard curves of real-time PCR for AR (A), FHL-2 (B) and SHP-1(C) genes 
performed on a dilution series of cDNA standard. Real-time PCR assay was analyzed in the linear phase and a fit linear 
function of the log of relative fluorescence vs. cycle number with a typical R
2






There is little information about the cell biology of the 
human prostate and about how hyperplasic and 
malignant lesions develop. The epithelial prostate cells 
(HNTEP) were established as an in vitro model to study 
the androgen dependence of human prostate and pre-
viously we showed that low concentrations of androgens 
exerted a positive effect on cell proliferation in HNTEP 
cells, and high concentrations maintained proliferation 
similar to that of the control (Pozzobon et al., 2012). In 
this study, the action of DHT treatment on AR, SHP-1 
and FHL-2 mRNA levels in HNTEP cells was estimated 
by quantitative analysis.  
HNTEP cells in primary culture expressed a functional 
AR. The AR mRNA levels were assessed after 4 h of 




M) alone or in 
association with hydroxyflutamide (OH-FLU) at 10
-6
 M 
and no effect on AR gene expression was observed 
(Figure 1) in these conditions. 
The expression of AR mRNA was detected in several 
cell types like LNCaP and the androgen-independent cell 
lines (DU-145 and PC-3) when transfected with AR 
(Alimirah et al., 2006). In this case, AR gene expression 
did not change with different treatments of DHT, but the 
addition of the anti-androgen agent hidroxyflutamide 
abolished the proliferative effect in HNTEP cells, giving 
support to the notion that the mitogenic effect of the low 
dose of DHT in HNTEP cells is regulated by its own 
receptor, the AR. These results are consistent with those 
of Mestayer et al. (2003) who reported that AR 










Figure 2. AR Protein. Autoradiogram of AR protein levels of 
HNTEP cells after 1 h (A) and 2 h (B) of incubation. Samples 
were separated in 8% SDS-PAGE, transferred to a 
nitrocellulose membrane and incubated with anti-AR antibody. 






Figure 3. AR expression in HNTEP cells. Graphic display the 
relative expression of AR gene. Each bar represents the mean 









between groups were analyzed by ANOVA followed by 
Duncan’s test. 




tissue. However in the immortalized cell lines PNT1A and 
DU-145, transfected with functional AR other author 
showed an increased activity in AR expression with DHT 
(10
-9
m) treatment (Avances et al., 2001). These 
controversial results may be explained by the different 
experimental models employed. The modulation of 
androgen receptor is a complex phenomenon which 
involves several mechanisms. It is important to note that 
the AR may also mediate important cellular functions in 
the cytoplasm, independent of its role as a transcriptional 
factor. For example, AR has been shown to participate in 
rapid signaling cascades which involve the activation of 
the MAPK pathway and thereby potentially induce a 
mitogenic reponse (White et al., 2005). The mechanisms 
underpinning the capacity of AR to induce a mitogenic 
program may be diverse and dependent on cell context. 
A study demonstrated in LNCaP that protein levels of AR 
were unaffected during 5 days of treatment with 5.10
-11 
M 
R1881, a very similar dose to the one used in our study 
(Nesslinger et al., 2003).  
The AR expression is influenced by several coregulator 
molecules, which facilitate domain interactions and 
consequently AR transativation. As a general definition, 
AR coregulators are proteins that are recruited by the AR 
and either enhance or reduce its transativation. More 
than 200 nuclear receptor coregulators have been iden-
tified since the isolation of the first nuclear receptor 
coactivator, SRC-1 in 1995 (Onate et al., 1995). The 
isolation of a multitude of proteins with AR coregulatory 
properties leads to speculation about the manner in 
which the formation of the AR transcriptional complex is 
orchestrated. The balance of corepressors and coactive-
tors in the AR complex determines AR transcriptional 
activity. In the present study, we observed an increase in 
the mRNA levels of SHP-1 when HNTEP cells were 
treated with a high dose of androgens. SHP-1 was 
described as an inhibitor of AR activity, and this result 
can indicate a negative modulation of AR with higher 
doses of androgens and consequently a lower prolife-
ration of HNTEP cells. The repression of AR activity by 
androgen treatment with 10
-9 
M R1881 was demonstrated 
in a monkey kidney cell line CV1 and in CHO cells, co-
transfected with a functional AR and SHP-1 (Gobinet et 
al., 2001). It is possible that the mechanism of SHP-1 
repression could be through competition with coactivators 
in AF-2 region, and this process depends on a higher 
concentration of SHP-1 or greater affinity (Jouravel et al., 
2007).  
In this article, we examined the role of the AR 
coregulator FHL-2. This gene does not bind to DNA, but it 
has an intrinsic transactivation domain and interacts with 
AR in a ligand-dependent manner (Kahl et al., 2006). 
Moreover, FHL-2 interacts with several AR-associated 
coactivators (Johannessen et al., 2006; Nair et al., 2007). 
However, the molecular mechanism by which FHL-2 
modulates AR transactivation remains unclear. FHL-2 
expression occurs in the cytoplasm of normal prostate
 









Figure 4.  FHL2 expression in HNTEP cells. Graphic display the relative expression of FHL2 gene. 





M) alone or in association with the antiandrogen hidroxyflutamide (OH-FLU.10
-6 
M). 





cells, and the degree of nuclear translocation increases in 
less-differentiated cancer cells (Muller et al., 2002). In our 
primary cell culture, we found an increase in mRNA 
levels of FHL-2 after incubation with a lower concentra-
tion of androgens, the same concentration that stimulated 
cellular proliferation. This effect was abolished by the 
anti-androgen agent OH-flutamide suggesting a positive 
modulation of androgen levels by FHL-2 in HNTEP cells. 
A study also described an increase in AR activity in CV1 
cells cotransfected with AR and FHL-2 and treated with 
androgens (Gobinet et al., 2001). Another study showed 
that a coregulator of multiple nuclear receptors, PELP1 
interacts with FHL-2 and synergistically enhances the 
transcriptional activity of FHL-2 in PC-3 cells 
cotransfected with MMTV-luc, β-Gal reporter gene and 
AR when incubated with androgen R1881. The same 
study has shown that FHL-2 also enhanced AR-mediated 
transativation of PSA promoter activity (Nair et al., 2007). 
Some authors did not show an FHL-2 expression in 
LNCaP cells (Nessler-Menardi et al., 2000), but the 
androgen induction of FHL-2 was demonstrated by 
Heemers (Heemers et al., 2007). The androgen exposure 
led to a marked increase in FHL-2 expression, both at the 






strated a time dependent androgen stimulation of FHL-2, 
reaching a maximum at 48 h. Finally, they also 
demonstrated the influence of FHL-2 in other androgen 
dependent genes containing androgen responsive 
elements (ARE) in their promoter regions.  
There are few studies regarding FHL-2 and SHP-1 
expression in the normal prostatic gland, and most of the 
data used immortalized cell lines. The dependence of AR 
coregulators to form a functional transcriptional complex 
suggests an important role in the development and 
maintenance of androgen-responsive tissues and can be 
involved in pathologies like benign prostatic hyperplasia 
and prostatic carcinoma.  
This is the first article that shows a relation between 
FHL-2 and SHP-1 expressions and androgen levels in 
human non-transformed prostatic cells. In summary, we 
showed that the expression of the AR coactivator FHL-2 
is stimulated by lower androgen concentrations whereas 
the corepressor SHP-1 is inhibited by this concentration 
and stimulated by higher androgen concentrations. We 
speculate that an increase in FHL-2 may lead to 
enhanced AR signaling or sensitize HNTEP cells to low 
levels of androgens and thus proliferate. This finding 
provides insights into the regulation of AR in prostatic 
diseases and identifies a possible mechanism by which 
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